Metabolic health of young adults who were born small for gestational age and treated with growth hormone, after cessation of growth hormone treatment: a 5-year longitudinal study.

What Was Tested

The paper reports a study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over), published as a clinical trial.

The researchers used dual-energy x-ray absorptiometry to assess body composition, and did frequently sampled intravenous glucose tolerance tests to assess insulin sensitivity, acute insulin response, and the disposition index (a measure of β-cell function).

Why It Was Studied

Data are only available for short-term longitudinal changes after cessation of growth hormone treatment in young adults born small for gestational age.

Who Took Part

By PubMed's age tags, the people studied were teenagers and young adults, both men and women.

The researchers did a longitudinal study of young adults born small for gestational age and previously treated with growth hormone.

How the Study Was Run

Data 5 years after cessation of growth hormone were compared with untreated age-matched controls.

This study is registered with ISRCTN, numbers ISRCTN96883876 and ISRCTN65230311.

What Was Measured

The subject headings attached to it are Absorptiometry, Photon, Adipose Tissue, Body Composition, Human Growth Hormone, Infant, Small for Gestational Age, Insulin Resistance and Longitudinal Studies.

What This Means in Plain Language

This is a clinical trial of Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

Results are reported in around 7 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2017 (The lancet. Diabetes & endocrinology), a journal based in England.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.